Category
Current Projects, Gene Therapy, Quality of Life Change
Tags
Abe Fund
About This Project

Replay next-generation gene therapy for DEB

Investment summary

Replay is advancing a next-generation gene therapy platform designed for RDEB. The platform uses an engineered herpes simplex virus (HSV) vector to deliver the COL7A1 gene, which encodes for Type VII collagen. The platform has shown promise in preclinical models.

Abe Fund contributed $100,000 to this project.